Blood drug levels may explain why some asthma patients Don't respond to mepolizumab
NCT ID NCT05495932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study measured the amount of mepolizumab in the blood of 50 adults with severe asthma who were already taking the drug. Researchers compared drug levels between those who responded well to treatment and those who did not. The goal was to see if differences in how the body processes the drug could explain why some patients don't get better. This was an observational study, not a test of a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Tours
Tours, France, 37044, France
-
university Hospital of Montpellier
Montpellier, France, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a single injection tame severe asthma in fungal allergy?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?